Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II

Molinaro, Caroline; Martoriati, Alain; Pélinski, Lydie; Cailliau, Katia

doi:10.3390/cancers12102863

Cited by 123 publications

(96 citation statements)

References 241 publications

(315 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other non-traditional alkylators are methylating agents, such as temozolomide used to treat glioblastoma [305]. Numerous metal-derived compounds, organometallics, are developed to generate severe DNA alterations [306,307]. Some ruthenium-containing compounds such as polynuclear ruthenium induce DNA damage and recruit DNA repair effectors such as XPC (Xeroderma Pigmentosum complementation group C) [308].…”

Section: Dna Damaging Drugsmentioning

confidence: 99%

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Molinaro

Martoriati

Cailliau

2021

Cancers

Self Cite

View full text Add to dashboard Cite

Cells respond to genotoxic stress through a series of complex protein pathways called DNA damage response (DDR). These monitoring mechanisms ensure the maintenance and the transfer of a correct genome to daughter cells through a selection of DNA repair, cell cycle regulation, and programmed cell death processes. Canonical or non-canonical DDRs are highly organized and controlled to play crucial roles in genome stability and diversity. When altered or mutated, the proteins in these complex networks lead to many diseases that share common features, and to tumor formation. In recent years, technological advances have made it possible to benefit from the principles and mechanisms of DDR to target and eliminate cancer cells. These new types of treatments are adapted to the different types of tumor sensitivity and could benefit from a combination of therapies to ensure maximal efficiency.

show abstract

Section: Dna Damaging Drugsmentioning

confidence: 99%

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Molinaro

Martoriati

Cailliau

2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Copper is essential element that participate in the reactions of various enzymes in the body, so copper-based complexes are promising anti-cancer drugs [ 100 ]. Lu et al designed and synthesized a series of copper(II) complexes of 9-substituted β-carboline [ 101 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting MCL-1 in cancer: current status and perspectives

et al. 2021

View full text Add to dashboard Cite

Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The central role of MCL-1 in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Significant progress has been made with regard to MCL-1 inhibitors, some of which have entered clinical trials. Here, we discuss the mechanism by which MCL-1 regulates cancer cell apoptosis and review the progress related to MCL-1 small molecule inhibitors and their role in cancer therapy.

show abstract

“…Interestingly, some copper (Cu 2+ ) complexes used in anticancer therapy inhibit topoisomerase 1 and 2, leading to DNA breaks and DNA fragments to activate cGAS signaling. 167 Notably, transporters for these ions have been observed dysregulated in cancer, 168 and it is plausible altered ion transport in cancer may facilitate cancer evasion of immune surveillance by modulating cGAS signaling. Although there is no direct evidence to support this speculation, it definitely warrants further investigations.…”

Section: Regulation Of Cgas Activation By Ionsmentioning

confidence: 99%

Cytosolic DNA sensing by cGAS: regulation, function, and human diseases

Liu

2021

Sig Transduct Target Ther

105

View full text Add to dashboard Cite

Sensing invasive cytosolic DNA is an integral component of innate immunity. cGAS was identified in 2013 as the major cytosolic DNA sensor that binds dsDNA to catalyze the synthesis of a special asymmetric cyclic-dinucleotide, 2′3′-cGAMP, as the secondary messenger to bind and activate STING for subsequent production of type I interferons and other immune-modulatory genes. Hyperactivation of cGAS signaling contributes to autoimmune diseases but serves as an adjuvant for anticancer immune therapy. On the other hand, inactivation of cGAS signaling causes deficiency to sense and clear the viral and bacterial infection and creates a tumor-prone immune microenvironment to facilitate tumor evasion of immune surveillance. Thus, cGAS activation is tightly controlled. In this review, we summarize up-to-date multilayers of regulatory mechanisms governing cGAS activation, including cGAS pre- and post-translational regulations, cGAS-binding proteins, and additional cGAS regulators such as ions and small molecules. We will also reveal the pathophysiological function of cGAS and its product cGAMP in human diseases. We hope to provide an up-to-date review for recent research advances of cGAS biology and cGAS-targeted therapies for human diseases.

show abstract

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II

Cited by 123 publications

References 241 publications

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Targeting MCL-1 in cancer: current status and perspectives

Cytosolic DNA sensing by cGAS: regulation, function, and human diseases

Contact Info

Product

Resources

About